Assetmark, Inc Adaptive Biotechnologies Corp Transaction History

Assetmark, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$2.88 - $4.8 $13,999 - $23,332	-4,861 Reduced 98.38%	80 $0
Q4 2023 Feb 09, 2024	BUY	$3.46 - $5.33 $5,183 - $7,984	1,498 Added 43.51%	4,941 $24,000
Q3 2023 Oct 27, 2023	SELL	$5.07 - $8.44 $3,153 - $5,249	-622 Reduced 15.3%	3,443 $18,000
Q2 2023 Aug 11, 2023	BUY	$6.19 - $8.78 $9,049 - $12,836	1,462 Added 56.17%	4,065 $27,000
Q1 2023 May 05, 2023	BUY	$7.8 - $10.11 $4,485 - $5,813	575 Added 28.35%	2,603 $22,000
Q4 2022 Feb 10, 2023	BUY	$6.26 - $9.34 $3,912 - $5,837	625 Added 44.55%	2,028 $15,000
Q3 2022 Nov 01, 2022	BUY	$6.5 - $12.67 $2,151 - $4,193	331 Added 30.88%	1,403 $10,000
Q2 2022 Aug 03, 2022	BUY	$6.4 - $14.73 $5,292 - $12,181	827 Added 337.55%	1,072 $9,000
Q1 2022 May 13, 2022	BUY	$10.12 - $28.9 $2,479 - $7,080	245 New	245 $3,000
Q2 2021 Aug 16, 2021	SELL	$32.22 - $44.59 $1,385 - $1,917	-43 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$37.26 - $67.74 $1,602 - $2,912	43 New	43 $2,000

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.